Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its proprietary multiple sclerosis therapy candidate, LUCID-MS, into patient-focused studies following positive safety data from Phase 1 clinical trials. The company reported that the therapy was generally well tolerated in healthy volunteers, supporting progression to Phase 2 trials in people living with multiple sclerosis.
LUCID-MS is designed to target demyelination and protect or restore myelin integrity, offering a potentially first-in-class approach that directly addresses myelin loss and neurodegeneration rather than relying solely on immune modulation. In April 2026, Quantum BioPharma submitted an Investigational New Drug application to the U.S. Food and Drug Administration, paving the way for the planned Phase 2 trial. The company is also strengthening operational support through a planned partnership with Allucent and engagement with neurological specialists.
Multiple sclerosis affects approximately 2.8 million people worldwide, and current treatments primarily focus on modulating the immune system to reduce relapses. LUCID-MS aims to reverse the underlying damage by promoting remyelination, which could potentially restore neurological function. The therapy is a patented new chemical entity that has shown ability to prevent and reverse myelin degradation in preclinical models.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of LUCID-MS. The company also retains ownership of 19.84% of Unbuzzd Wellness Inc., which markets the OTC version of unbuzzd, and receives royalty payments from sales.
For more information, visit the company’s newsroom at https://ibn.fm/QNTM. The full article can be viewed at https://ibn.fm/AUhNl.
InvestorWire is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN. For more information, visit https://www.InvestorWire.com.
